The Roche Elecsys® Alzheimer’s CSF Assays
New Alzheimer’s therapies are here and offer real hope to patients and families — but only if a patient’s disease is diagnosed in the early disease stages (mild cognitive impairment to mild dementia).1 In patients 55 years or older, the Elecsys® CSF assays can efficiently detect amyloid pathology, opening access to new Alzheimer’s therapies.2,3,4
The Elecsys Phospho-Tau (181P) CSF (pTau181) and -Amyloid (1-42) CSF II (Abeta 42) and Elecsys Total Tau CSF (tTau) and -Amyloid (1-42) CSF II (Abeta 42) ratios have a ~90% concordance with amyloid PET, and the assays are traceable to reference materials to ensure accuracy. 2,5
The following assets provide background information on and sample collection protocols for Roche’s AD CSF offerings. Please contact your lab director/partner to receive the test package insert/method sheet.
Please contact your lab leadership if you need more information regarding the Elecsys Alzheimer’s CSF tests.
Alzhemer’s CSF Collection Protocol Information:
Alzheimer’s CSF Patient Information:
Alzheimer’s CSF Background Information:
References:
1. alzint.org/about/symptoms-of-dementia/importance-of-early-diagnosis,
Accessed Feb. 16, 2024
2. Elecsys® Method Sheet: ms_08821941190, ms_08846693160, ms_08846685190
3. Cummings, J., Apostolova, L., Rabinovici, G.D. et al. Lecanemab: Appropriate Use
Recommendations. J Prev Alzheimers Dis (2023)
4. Cognat E, et al. BMJ Open. 2019;9(5):e026380.
5. Hansson O, et al. Alzheimers Dement. 2018;14(11):1470-1481.
Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. © 2025 Roche Diagnostics